Phone Number
(800) 210-7017
(800) 210-7017
Here’s what most clinics get backwards: they treat a PRP kit like a shopping decision when it’s really a clinical one. Before you ever look at a price sheet, you’ve got to know what you want happening on the scalp, then judge every kit against that target. The right kit isn’t the cheapest one or the one with the loudest marketing, it’s the one that drops a consistent, clean, well-characterized platelet product into the workflow you already run.
A kit that reliably yields a three-to-five-fold platelet concentration with low red and white cell contamination inside the clinic’s existing workflow outperforms one chosen on headline price alone.
You’re not buying a kit, you’re buying a result that has to repeat patient after patient. What a hair practice actually wants is measurable growth in hair density and caliber, the kind you can track with standardized scalp photos, phototrichograms, or hair counts in a fixed zone. The thing that separates a real outcome from a lucky one is reproducibility, so a kit that hits the same concentration every time lets you standardize dosing and build a protocol you can defend.
A kit that delivers a tightly characterized platelet concentration on every patient lets a clinic standardize dosing and build a defensible treatment protocol, while a variable kit makes results impossible to attribute.
The technical layer is where kits actually diverge, and if you only read marketing claims you’ll miss the variables that predict performance. A kit advertising a five-fold concentration but recovering only a sliver of the patient’s platelets behaves nothing like one with moderate concentration and high recovery. Knowing where a candidate sits on each axis below means you’re reading the device, not the brochure.
A system that needs sixty milliliters of blood to yield a few milliliters of PRP imposes a very different patient experience than one working from a smaller draw, so draw-to-yield ratio is as decisive as concentration.
Regulatory standing is the gate every other consideration has to pass through, because a kit you can’t lawfully use is worthless no matter how good its yield. These devices are usually regulated as the kit-and-centrifuge combination rather than the PRP itself, and the cleared intended-use statement governs how you’re allowed to describe and apply the therapy. Treat the paperwork as a screening filter early, before you fall for a kit you can’t legally stand behind.
A kit’s cleared intended-use statement governs how a clinic may describe and apply the therapy, and overstating indications beyond that scope creates direct compliance exposure.
This is the most common fork a hair clinic faces, and the honest answer is that each protocol wins on different axes rather than one being flat-out better. Single-spin runs the blood through one centrifugation, which is faster and more forgiving but tends to leave more leukocytes and red cells in the product. Double-spin adds a second, harder pass that pellets the platelets for a cleaner, more tunable, leukocyte-poor preparation many practitioners prefer for scalp comfort.
| Criteria | Single-Spin | Double-Spin |
|---|---|---|
| Processing speed | Faster, one pass | Slower, second spin |
| Concentration factor | Lower | Higher, more tunable |
| Leukocyte content | More residual | Cleaner, leukocyte-poor |
| Operator dependence | More forgiving | More technique-sensitive |
| Best fit | High-throughput practices | Characterized scalp product |
For scalp injection where a characterized, leukocyte-poor product matters, double-spin or a well-validated buoy single-spin system often edges ahead, while a high-volume practice may rationally pick a robust single-spin gel system for speed and reproducibility.
The number that should drive your economics is fully loaded cost per treatment, not the sticker price on the kit box. Clinics that compare only the headline figure routinely misjudge their margins, because the kit is just the most visible line item. True cost lives in the full case, and labor is the piece that gets ignored most often even though it can rival the kit price on a long protocol.
Fully loaded cost per treatment, including the kit, every consumable, labor, and amortized centrifuge time, is the only figure that lets a clinic set a defensible patient price that preserves margin.
A kit that performs beautifully in a one-patient demo can still be the wrong call once real throughput, equipment, and staffing are layered in. The right kit is the one whose format dissolves into your existing rhythm, not the one with the best spec sheet sitting in isolation. Here’s how the major variables sort into clear scenarios.
Each kit is validated for specific centrifuge speeds and rotor geometries, so a kit that does not fit the clinic’s existing machine forces either a capital purchase or a workaround that voids the validated yield.
The downside of a poor kit choice shows up as patient safety risk long before it ever shows up on a balance sheet, which is exactly why risk deserves explicit weight in the decision. The most serious hazard is microbial contamination, and it scales directly with how often the blood touches open air. Inject a contaminated product into the scalp and you can produce abscesses or folliculitis, the kind of adverse event that no price saving can offset.
Injecting a contaminated product into the scalp can produce abscesses or folliculitis, and the risk scales directly with how often the blood is exposed to open air, making a closed system a direct control on the worst adverse events.
A PRP kit isn’t a one-time purchase, it’s an ongoing dependency, so you should evaluate the relationship you’re entering, not just the product you’re buying. Once your patients expect continuity on a standardized protocol, a manufacturer with erratic lead times can strand you mid-protocol. The kit that earns long-term trust is backed by a vendor who behaves like a partner across years, not a counterparty at the moment of sale.
Once a clinic invests in a centrifuge calibrated to a specific kit, switching systems carries real friction in retraining, re-validation, and possible new capital, so the durability of that commitment should be weighed before it is made.
The way to turn all of this into a defensible choice is a deliberate, staged evaluation, not a quick flip through brochures. An advertised yield is only a promise until you reproduce it on your own centrifuge, so hands-on validation is the stage that actually decides things. Score the finalists on an explicit matrix, run a small pilot, and write down the rationale so you’ve got both an audit trail and a baseline to revisit later.
A kit’s advertised yield is only a promise until it is reproduced on the clinic’s own centrifuge, which makes hands-on validation the decisive stage of any structured evaluation.
